Denali Therapeutics Inc. (DNLI) Tops Q4 EPS by 2c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q4 EPS of ($0.73), $0.02 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
• Citi raises Deere price target to $650, keeps Neutral rating
• Walmart (WMT) PT Lowered to $130 at Guggenheim